X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, NCATS will gain access to proprietary novel proteolysis-targeting degraders of TEAD, including YAP–TEAD, from Beactica to evaluate their efficacy in disease-relevant preclinical models for treatment of cancer.
Lead Product(s): YAP–TEAD
Therapeutic Area: Oncology Product Name: YAP–TEAD
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Center for Advancing Translational Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 26, 2023
Details:
Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST.
Lead Product(s): BEA-17
Therapeutic Area: Oncology Product Name: BEA-17
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oscotec
Deal Size: $178.0 million Upfront Cash: Undisclosed
Deal Type: Termination April 04, 2023
Details:
BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of the epigenetic enzyme LSD1 and its co-factor CoREST. The compound has shown promising preclinical in vivo potentiation of immune-modulating treatments in several cancer forms.
Lead Product(s): BEA-17
Therapeutic Area: Oncology Product Name: BEA-17
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dong-A ST Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 06, 2022
Details:
Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oscotec
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
